Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
494.46
+8.13 (+1.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
Next >
Earnings Outlook For argenx
March 01, 2023
Via
Benzinga
Immunovant Could Potentially Be An M&A Target, Writes Analyst
February 15, 2023
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
Analyst Ratings for argenx
January 10, 2023
Via
Benzinga
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
January 10, 2023
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in...
Via
Benzinga
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
December 22, 2022
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading.
Via
Benzinga
Analyst Ratings for argenx
December 07, 2022
Via
Benzinga
Expert Ratings for argenx
December 07, 2022
Via
Benzinga
7 Analysts Have This to Say About argenx
October 18, 2022
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
November 30, 2022
Via
Benzinga
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
November 22, 2022
Via
Benzinga
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
October 28, 2022
Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at...
Via
Benzinga
Recap: argenx Q3 Earnings
October 27, 2022
argenx (NASDAQ:ARGX) reported its Q3 earnings results on Thursday, October 27, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx missed estimated earnings by...
Via
Benzinga
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
September 29, 2022
Via
Benzinga
Argenx's Drug Scores European Approval For Muscular Fatigue Disorder
August 11, 2022
Via
Benzinga
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike
July 29, 2022
Via
Benzinga
argenx: Q2 Earnings Insights
July 28, 2022
argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: argenx Q2 Earnings
July 28, 2022
argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
October 12, 2022
Upgrades
Via
Benzinga
What 5 Analyst Ratings Have To Say About argenx
July 25, 2022
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter:
Via
Benzinga
SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space
May 24, 2022
Via
Benzinga
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study
May 05, 2022
Via
Benzinga
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection
September 21, 2022
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 11, 2022
Via
Benzinga
Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate
August 11, 2022
The European Commission (EC) has granted marketing authorization for Argenx’s (NASDAQ: ARGX) lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
July 29, 2022
Via
Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
July 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know
July 25, 2022
Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00. Shares of argenx are trading up 1.84% over the last 24 hours, at...
Via
Benzinga
Golden Cross Appears Before argenx Investors
May 16, 2022
If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.